To discuss the changing landscape and significant developments in the diagnosis and management of oropharyngeal squamous cell carcinoma.
INTRODUCTION
Worldwide, the incidence of pharyngeal carcinoma is approximately 136 000, with oropharyngeal squamous cell carcinoma (OPSCC) on the rise in developed countries [1,2 && ]. The proportion of all head and neck squamous cell cancers (HNSCCs) arising in the oropharynx has risen from 20% in the 1980s to 70% in the United States at present [3 && ,4] . This increase has been linked to a rise in human papilloma virus (HPV)-associated cancers [5, 6] . Epidemiologic studies indicate oral HPV infection is predominantly sexually acquired [7] . A generational change in sexual behavior may have contributed to the surge in HPV-associated OPSCC [8, 9] .
The scope of this review is to highlight the standards of care for managing oropharyngeal cancer, and how these are forecast to change for HPV-associated and HPV-nonassociated OPSCC, given a current generation of studies exploring treatment deintensification for favorable prognosis cancers, and testing novel targeted therapies in intermediate and unfavorable prognosis cancers.
THE DISTINCT CLINICAL PHENOTYPES, MOLECULAR BIOLOGY, AND TESTING OF OROPHARYNGEAL CANCER
Patients with HPV-associated cancer have a younger median age, and lower lifetime exposure to tobacco and alcohol, than patients with HPV-unrelated cancers (Table 1) [9, 10 distinct pathogenesis [9,11 & ]. Following viral integration, HPV E6/E7 oncoproteins promote cell cycle progression in keratinocytes by inactivating two important tumor suppressor genes, the tumor protein p53 and Rb. Rapid degradation of p53 results in low levels of intact wild-type p53, whereas Rb inactivation induces the cyclin-dependent kinase inhibitor p16 [9,11 & ]. The inactivation of p53 can foster activation of the Wnt signaling pathway [12] and specific mutations in PIK3Ca have been described in HPV-associated OPSCC [13] . In contrast, HPV-negative OPSCCs are characterized by high mutational burden, with p53 mutation and activation of the PI3K pathway via mutation or phosphatase and tensin homolog (PTEN) loss the most common abnormalities [14] [15] [16] . The enhanced sensitivity to radiation and chemotherapy of HPV-associated cancers is not fully explained [17, 18] . Differences between these two cancers include frequent p53 mutation in HPV-negative cancers; differential expression of other genes associated with treatment resistance such as TYMS, STMN1, CCND1, and RBBP4; and enhanced immune clearance of virally infected cells following radiation injury [19, 20] .
HPV DNA is detected by several methods, including type-specific and broad-spectrum in-situ hybridization (ISH), PCR-based amplification assays, real-time PCR to quantify viral load, and immunohistochemistry (IHC) for p16, upregulated following oncoprotein E7-induced Rb degradation [21, 22] . p16 IHC is a reliable surrogate marker (sensitivity, 96.8%; specificity, 83.8%) comparable to ISH (sensitivity, 88.0%; specificity, 94.7%) [21,22,23 && ,24] . The discordance between p16 IHC and HPV ISH for HPV 16, the type of HPV most commonly associated with OPSCC, is about 25%. p16-positive/HPV 16-negative cases may be associated with a different HPV genotype. A liquid phase
KEY POINTS
Oropharyngeal carcinoma is on the rise in developed countries.
High-risk HPVs have been recognized as important causative factors for oropharyngeal cancer.
HPV-associated OPSCC has a distinct clinical and molecular biology compared with HPV-negative OPSCC.
Treatment response and survival outcomes in HPVassociated OPSCC are superior compared with HPVnegative OPSCC.
Clinical trials focus on de-escalation of treatment in select group of HPV-associated OPSCCs, and intensification of treatment with addition of novel targeted agents to standard treatment in HPV-negative OPSCC. assay used in cervical cancer is being tested with HNSCC [21, 25] .
RISK STRATIFICATION AND IDENTIFICATION OF FAVORABLE OROPHARYNGEAL CANCER
Prospective and retrospective studies have helped us understand the impact of smoking on oropharyngeal cancer prognosis. Ang et al. [26] retrospectively evaluated a subgroup of 433 patients with oropharyngeal cancer treated on RTOG 0129, a randomized trial comparing accelerated fraction chemoradiation (CRT) to standard fraction radiation therapy. Tissue was available for HPV testing in 63.8%. The 3-year overall survival and progression-free survival (PFS) were significantly better in the HPV-positive than the HPV-negative patients [hazard ratio 0.42 (95% confidence interval 0.27-0.66) P <0.001]. A recursive partition analysis (RPA) explored smoking history of less than 10 years vs. more than 10 years, nodal stage and tumor stage, yielding three putative risk categories: favorable risk HPV-associated cancer in nonsmokers, intermediate risk consisting of HPVassociated cancers with tobacco exposure and high nodal stage, or HPV-negative cancers with intermediate tumor stage, and high risk consisting of HPV-negative cancers with high tumor stage. Table 2 illustrates the differences in outcomes in the various risk groups.
O'Sullivan et al. [27 && ] conducted a similar RPA in a retrospective study with over 800 oropharyngeal cancer patients treated with radiation or concurrent CRT at a single institution between 2001 and 2009. HPV status was determined in 56%. HPV association was demonstrated in 382 patients. RPA stratified patients on HPV status, T stage, and nodal stage ( Table 2) . Smoking status was not identified as a significant risk factor for distant metastases. Conversely, the risk of developing a second primary was significantly higher in patients with more than 10 pack-year smoking history (11 vs. 4%, P ¼ 0.009). HPV-associated disease manifested a more indolent natural history, with development of distant metastases occurring until 5 years of followup, in contrast to most distant failures occurring in the first 2 years in HPV-negative cases.
GENERAL PRINCIPLES IN THE TREATMENT OF OROPHARYNGEAL CANCER
Upfront surgery and radiation alone, for early stage (T1-T2 N0) oropharyngeal cancer, are equally effective in locoregional control and overall survival [28 && ]. For patients with early nodal involvement (T1N1, T2N1), resection of the primary tumor with neck dissection or adjuvant radiation is effective. Radiation Therapy Oncology Group (RTOG) study R0920 [NCT00956007] examines whether the addition of cetuximab to radiation in intermediaterisk patients without classic indications for chemoradiation improves outcome in the adjuvant setting.
For patients with more advanced T stage and nodal stage (stage III, IVa, and IV b), concurrent high-dose cisplatin with radiation has been considered optimal treatment since the publication of the Intergroup trial [29] . These findings are also supported by meta-analysis [30] . Chemoradiation emerged as the preferred treatment because of the morbidity associated with conventional surgical approaches to oropharyngeal cancers, which required morbid exposures and generally involved total glossectomy. The advent of transoral surgical approaches for T1 and T2 oropharyngeal cancers has reopened the question of when resection belongs in standard management. Sequential therapy with multiagent induction chemotherapy followed by standard CRT has been explored as an approach to improve outcome, but randomized trials have failed to demonstrate a benefit in unselected patients [31
. Although organ preservation with concurrent high-dose cisplatin with 70 Gy radiation is standard of care for locally advanced OPSCC, these patients are at risk for developing long-term toxicities secondary to damage to pharyngeal constrictor muscles, salivary glands, skin, and thyroid gland. The risk of dysphagia increases above 55 Gy radiation dose to superior and middle pharyngeal constrictors [33 & ]; feeding tube dependence increases when more than 30% of the pharyngeal constrictors receive 70 Gy [34] ; and stricture and aspiration are more common if 50% of the pharyngeal constrictors receive 70 Gy [33 & ]. Additionally, xerostomia [35] , radiation dermatitis [36] , chronic cosmetic changes [36] , and hypothyroidism [37] are also associated with higher radiation dose and volume. Long-term follow-up of patients treated curatively for larynx cancer with high-dose radiation and high-dose cisplatin also raises the possibility that CRT increases noncancer mortality [38] .
FUTURE DIRECTIONS IN THE TREATMENT OF OROPHARYNGEAL CANCER
The HPV-associated oropharyngeal cancer patients are relatively younger individuals, with a lower burden of comorbidity and excellent prognosis. E2399 treated patients with oropharynx and larynx cancer with induction chemotherapy followed by 70 Gy with concurrent paclitaxel, in an early attempt at reducing treatment morbidity in unselected patients [18] . Prospective subset analysis demonstrated that for HPV-positive compared with HPV-negative patients, objective response (81.6 vs. 55.2%, P ¼ 0.01) and 2-year PFS were markedly superior (84.2 vs. 56.9%, P ¼ 0.06).
Tissue samples from oropharyngeal cancer patients enrolled on phase III trials RTOG0129 (discussed above) [26] , TROG 02.02 [39] , TAX 324 [40] , and DAHANCA [17] all reported that for 3-year and/or 5-year survival, HPV-positive/p16-positive patients had a significant advantage ( Table 3 ).
Human papilloma virus-associated disease: de-escalation clinical trials in progress
Given the difference in cause, molecular profile, natural history, and treatment responsiveness, investigators have concluded that HPV-associated and HPV-unrelated oropharyngeal cancer are two different diseases, and that different research questions arise in the two diseases. For HPV-positive cancer, it will be important to develop reliable tests -whether based on clinical criteria or on validated biomarker panels -to select patients with a very high chance of cure, and to find treatments for these patients which are less arduous, and which are associated with the least possible risk of longterm toxicity and of noncancer mortality. For HPVassociated cancer with a greater risk of recurrence, defining the causes of failure and adapting treatments to address these causes will be important. For the HPV-negative locally advanced patient, who currently appears to have only a 35% chance of cure, identification of novel targets, and incorporation of new agents, will be critical to improved outcomes.
Several strategies have been explored, which are discussed below. De-escalating treatment with upfront induction chemotherapy followed by response adapted radiation (low vs. standard) with an alternative radiosensitizer E1308 [NCT01084083], a prospective phase II trial designed specifically for HPV 16 ISH or p16-positive, stage III, IVa oropharyngeal cancer patients, completed accrual in 2011 (ASCO 2013, Abstract 6005). Treatment included induction chemotherapy with three cycles of cetuximab/paclitaxel/cisplatin to identify the most treatment-responsive patients, who then received 54 Gy rather than 69 Gy radiation with concurrent cetuximab. With a median followup of 16.2 months, the 1-year PFS in the low-dose arm in patients with less than 10 pack-year smoking history was 97% (95% confidence interval 0.83-0.99). Follow-on studies planned within the Eastern Cooperative Oncology Group (ECOG) include a trial to examine whether the dose to next echelon nodes can be reduced, what the least toxic induction regimen to identify the 70% of patients who are eligible for radiation de-escalation is, and whether cisplatin or cetuximab is the preferable radiosensitizer. These developmental studies are anticipated to lead to an optimal low toxicity approach to deintensification, which will be appropriate for phase III testing against conventional full-dose CRT with high-dose cisplatin. RTOG proposes to test treatment deintensification from 70 to 60 Gy with no radiation sensitizer in a comparable population.
De-escalating treatment by optimizing the type of radiosensitizer with standard dose radiation RTOG 1016 [NCT01302834], a phase III trial comparing weekly cetuximab with accelerated radiation therapy 70 Gy/6 weeks to cisplatin 100 mg/m 2 d1 and 22 with accelerated radiation therapy 70 Gy/6 weeks in patients with p16-positive, T1-2, N2a-N3 and T3/4 any N, oropharyngeal cancer, reached its initial accrual goal in mid 2013, but proved to have a lower event rate than projected. It has recently reopened with an increased sample size of 834. This study is the first trial to compare cisplatin with cetuximab as a radiosensitizer in a homogeneous population.
De-escalating treatment using upfront surgery with minimally invasive techniques followed by reduced dose radiation in the adjuvant setting Previously, surgery for oropharyngeal cancer required transcervical neck exposure and resulted in significant morbidity. Minimally invasive techniques for transoral resection have emerged [28 && ].
To date, the experience with these techniques, specifically on tonsillar and base of tongue T1 and T2 OPSCC, has reported excellent long-term swallowing outcomes. ECOG 3311 [NCT01898494] is a phase II trial in p16-positive resectable stage III, IVa and b oropharyngeal cancer. All patients will undergo transoral resection and neck dissection, followed by risk-adapted adjuvant therapy. Patients with pathological stage I and II are considered at low risk for recurrence and will enter the observation arm. Patients with less than 1 mm extracapsular extension (ECE), two to four positive lymph nodes or close margins, will be considered at intermediate risk. These patients will be randomized to 50 vs. 60 Gy radiation. The high-risk groups are those with positive margins, with more than 1 mm ECE, or at least five positive lymph nodes. These patients will receive 66 Gy with weekly cisplatin. This study hopes to demonstrate that transoral resection followed by reduced dose adjuvant radiation can maintain a 2-year PFS of 85% or better in the intermediate-risk group.
Human papilloma virus-negative disease: treatment intensification with novel targeted therapy
As noted above, decades of trials examining longer duration and intensity of therapy [31 & ,41] , accelerated fractionation in chemoradiation, and the addition of novel agents to CRT [26, 42] , have failed to advance survival for patients with HPV-negative cancer. Data from a randomized phase II trial suggest the possibility that the dual EGFR/HER2 inhibitor lapatinib added to CRT improves disease control and survival in HPV-negative HNSCC, and have led to the design of an RTOG Foundation study of lapatinib and CRT in p16-negative HNSCC [NCT00490061] [43 & ]. Another dual EGFR-HER2targeted agent is the irreversible inhibitor afatinib. This tolerable and orally administered agent is active in HNSCC and opened up the opportunity for long-term adjuvant therapy in patients who have no evidence of disease following CRT, but are at high risk of recurrence by virtue of tobacco history or stage and subsite. These patients are eligible for 2 : 1 randomization between afatinib and placebo on a trial powered for disease-free and overall survival [NCT01427478]. Additional novel targets of interest in this population are aurora A kinase [NCT01540682] [44 & ], tubulin [45] , EGFR [46] , and the PI3K pathway, now recognized to be the most commonly deranged pathway in these cancers [NCT01111058; NCT01602315; NCT01737450] ( Table 4 ).
An important new direction in anticancer therapy has been the ability to target T-cell exhaustion. Both in HPV-associated and HPV-unrelated HNSCC, it seems likely that a subset of PD-L1expressing cancers will benefit from this approach, with phase I trials ongoing and trials through phase III currently under development.
CONCLUSION
The oropharyngeal cancer landscape is swiftly changing and the number of HPV-associated oropharyngeal cancers is expected to surpass the number of cervical cancers by 2020 [4] . Investigators now hope to devise different treatment paradigms for optimal management of OPSCC based on HPV status, tumor stage, nodal stage, and smoking history. Important research questions will be the most accurate means of identifying highly curable patients, the least toxic treatment approaches that do not sacrifice cure in favorable risk patients, and identifying new agents and paradigms for patients who currently do not have a high expectation of cure. 
